Cover Image


Drug Reconstitution Systems for Self-Administration

出版商 Greystone Research Associates 商品編碼 329797
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
自我施打的藥物重組系統 Drug Reconstitution Systems for Self-Administration
出版日期: 2015年05月13日 內容資訊: 英文





  • 注射用製劑的成長
  • 重組:生物製藥的利用期限
  • 冷凍乾燥製劑的經濟合理性


  • 自我施打趨勢
  • 人口動態的變化
  • 對患者的服藥指導與其遵守
  • 慢性疾病的盛行率與發病率
  • 治療需求的推進因素


  • SC/IM注射用製劑
  • 注射用藥物
  • 細胞毒性醫藥品
  • 其他


  • 質樸、使用的容易度
  • 人機學/人體工學
  • 患者人口係數
  • 治療方面的影響因素、規定
  • 用戶的回饋與確信


  • 已上市設備
  • 已填充稀釋液注射器
  • 專用重組設備
  • 單步雙心腔型設備
  • 新的設備


  • 分析
  • 自體免疫疾病
  • 血液因子
  • 荷爾蒙
  • 感染疾病
  • 代謝系症狀
  • 生殖健康
  • 其他重要的治療層級


  • 法律規章上的課題
  • 患者的安全
  • 醫療的經濟學


Product Code: DRS755K

The Evolving Landscape for Reconstitution Devices


The inherent instability of protein drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed - a requirement referred to as the 'cold chain'. Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are increasingly being sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection. Drug Reconstitution Systems for Self-Administration examines the impact of reconstitution at the point of self-administration on injectable drug markets.

The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.

Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

What You Will Learn

  • What is the impact of lyophilized injectable drugs on today's therapeutic market, and who markets them?
  • Who are the suppliers of point-of-care reconstitution devices, and what is their market impact?
  • What are the major factors driving point-of-care drug reconstitution demand?
  • What is the relative impact of integrated reconstitution systems to standard reconstitution devices and how will this change by the end of the decade?
  • What are the essential design factors, material selection issues, technologies and market development issues for drug reconstitution systems and devices?
  • What is the role of point-of-care drug reconstitution systems on drug life cycle management?
  • What are the significant economic, technology, and regulatory factors affecting the market for injectable drugs and reconstitution systems?

Table of Contents

Summary of Contents

  • Executive Summary
  • The Drug Reconstitution Market Landscape
  • Injectable Drug Growth
  • Reconstitution - A Fact of Biological Drug Life
  • The Economic Rationale for lyophilized Drugs
  • User-Friendly Reconstitution - The Market Opportunity
  • The Trend toward Self-Administration
  • Shifting Demographics
  • Patient Compliance and Adherence
  • Chronic Disease Incidence and Prevalence
  • Therapeutic Demand Drivers
  • Recon Market Segments & the Total Addressable
  • Market
  • Drugs for SC/IM Injection
  • Drugs for Infusion
  • Cytotoxic Drugs
  • Other Market Segments
  • Drug Reconstitution Device Design & Selection Factors
  • Simplicity and Ease of Use
  • Human Engineering/Ergonomics
  • Patient Population Factors
  • Therapeutic Factors and Limitations
  • User Feedback and Confirmation
  • Drug Reconstitution Devices - Profiles and Analysis
  • Marketed Devices
  • Prefilled Diluent Syringes
  • Proprietary Reconstitution Devices
  • Single Step Dual Chamber Devices
  • New and Emerging Devices
  • Self-Administered Reconstitution Therapeutic Sector
  • Analysis
  • Autoimmune Diseases
  • Blood Factors
  • Hormones
  • Infectious Diseases
  • Metabolic Conditions
  • Reproductive Health
  • Other Important Therapeutic Classes
  • Market Factors
  • Regulatory Issues
  • Patient Safety
  • Healthcare Economics
  • Company Profiles
Back to Top